



YOUNG ONCOLOGIST CLUB



INTERNATIONAL MEETING OF
YOUNG ONCOLOGIST CLUB

Precision Medicine - the Key to Success in Cancer Therapy

Hyatt Pravets, May 17-19, 2024

FRIDAY, MAY 17, 2024 (DAY 1)

Conference opening/Welcome addresses – Young Oncologist Club Bulgaria,
Balkan Investigation Network of Oncology, European Chinese Alliance of Oncology

Hall Pravets

LUNG CANCER SESSION

Moderators: Chr. Manegold & S. Kutov & B. Iliev & G. Ganey

- 11.00 – 11.20 Innovations in Diagnostics to Overcome Challenges in Lung Cancer Screening, W. Voigt
- 11.20 – 11.40 Molecular Diagnostics of NSCLC and SCLC, M. Papotti
- 11.40 – 12.00 Management of SCLC, S. Baka
- 12.00 – 12.20 New Developments in NET Treatment and Response Assessment, G. Santo
- 12.20 – 12.40 SNMMI/EANM Practice Guideline for Palliative Nuclear Medicine Therapies of Bone Metastases – 2023, R. Mititelu
- 12.40 – 13.00 Resectable Non-Mutant NSCLC: Current Peri-Operative Medical Management, Chr. Manegold
- 13.00 – 13.20 Immunotherapy for NSCLC - Cases and Challenges from the Clinical Practice, N. Chilingirova
- 13.20 – 14.20 Lunch
- 14.20 – 14.40 Toxicity of Immune Therapies: Diagnosis and Management in China, J. Wang
- 14.40 – 15.00 Management of Stage III NSCLC, M. Huang
- 15.00 – 16.00 Interactive Tumor Board - R. Krasteva, A. Konsoulova, N. Chilingirova, Chr. Manegold, G. Santo, B. Iliev, P. Balikova, S. Kutov, Ts. Tatarov, J. Niklinski

Hall Pravets

16.00 – 17.00 Symposium Pierre Fabre

Moderator: N. Chilingirova

Challenges and Benefits in the Treatment of BRAF V600E Mutated mCRC Patients, M. Liontos
Long-Term Benefits of Encorafenib + Binimetinib in the Treatment of BRAF Mutant Melanoma Patients. Sharing of Clinical Case from the Real-World Practice, R. Yonchev

17.00 – 18.00 Symposium Johnson & Johnson

Amivantamab - The First Immunotherapy Approved for NSCLC with EGFR exon 20 ins.

Moderator: R. Krasteva

Precision Diagnostics of NSCLC - Practical Guidelines, S. Bachurska
Amivantamab – The First Immunotherapy Approved for NSCLC with EGFR exon 20 ins.
Diagnostic and Therapeutic Challenges in this Patient Subpopulation, T. Zlatanova

18.00 – 19.00 Symposium MSD

Moderator: R. Krasteva

TNBC: an Evolving Treatment Landscape, R. Bartsch, J. Arabadjiev

19.00 – 19.40 Symposium Zentiva

Iron Deficiency Conditions Accompanying Oncological Diseases. Current Approaches and Guidelines for Oral Iron Supplementation.

Hall Monovets

16.00 – 17.00 Symposium Astra Zeneca

CareForward: Merging Practice with Progress in Ovarian, Lung, & Breast Oncology

Moderator: R. Krasteva

Bridging Innovation and Real-World Oncology in the Treatment of Ovarian Cancer, A. Gerasimov
Bridging Innovation and Real-World Oncology in the Treatment of Lung Cancer, M. Musin
Bridging Innovation and Real-World Oncology in the Treatment of Breast Cancer, B. Iliev

17.00 – 17.20 Lecture Bayer

The role of Nubeqa in Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Carcinoma, S. Kutov

17.20 – 17.40 Lectures Roche

Sharing a Clinical Case of Patient with Metastatic NSCLC, V. Milov
Therapeutical Options with Tecentriq for Patients with Metastatic NSCLC and ES-SCLC, M. Kanarev

17.40 – 18.00 Lecture Medison Pharma

Into the “Eye” of the Cytokine Storm - Managing the Immune Response in Stormy Weather
Using a First-in-Class Cancer Therapy in Metastatic Uveal Melanoma, A. Konsoulova

18.00 – 18.20 Lecture Servier

Lonsurf: Daily Clinical Practice Data, A. Changelova

18.20 – 18.40 Lecture Teva

Lonquex - Data from Real Clinical Practice, S. Nedeva

18.40 – 19.00 Lecture Ewopharma

New Approaches for Thyroid and Endometrial Cancer Treatment, N. Tsigarovski

19.00 – 19.20 Lecture Amgen

Exploring Novel Approaches for Improved Patient Outcomes, B. Iliev

Hall Borovets

16.00 – 19.00 Pathology Workshop, M. Papotti

20.00 – 23.00 Dinner

SATURDAY, MAY 18, 2024 (DAY 2)

Hall Pravets

BREAST CANCER SESSION

Moderators: A. Gerasimov & A. Fakirova & Y. Yordanov & G. Ganey

- 09.00 – 09.30 Breast Cancer Diagnosis during Pregnancy, F. Zagouri
- 09.30 – 10.00 Prophylactic Mastectomy: an Appraisal, G. Zografos
- 10.00 – 10.30 Immunotherapy in Breast Cancer, Chr. Zielinski
- 10.30 – 10.50 Cancer Treatment during Pregnancy. Evidence for Maternal and Fetal Safety, Ch. Lejeune, F. Amant
- 10.50 – 11.10 Navigating Precision Medicine: The Power of Molecular Tumor Board in Clinical Decision Making, Moderator: R. Krasteva; J. Niklinski, J. Kisluk, B. Iliev
- 11.10 – 11.30 Personalization of Breast Cancer Postoperative Radiotherapy Based on Neoadjuvant Systemic Treatment Response - Current Status and Debates, T. Hadjieva

OTHER CANCER LOCALIZATIONS SESSION

Moderators: S. Nedeva & A. Kontilev & T. Karanikolova

- 11.30 – 11.45 Clinical Application of SPECT/CT Imaging of NEPC, S. Sergieva
- 11.45 – 12.00 Comparison of Baseline 68Ga-FAPI and 18F-FDG PET/CT for Prediction and Treatment Response in Patients with Oncological Diseases, R. Mei
- 12.00 – 13.00 Workshop Young Oncologists Competition – Compare our Knowledge – Interactive Session
- 13.00 – 14.00 Lunch
- 14.00 – 14.15 Differentiated Thyroid Cancer – New Approach for Application of I-131, J. Mihailovic
- 14.15 – 14.30 How to Write Diagnoses – Latin versus Bulgarian, R. Krasteva, A. Konsoulova
- 14.30 – 14.50 Round Table – Drug Pathway – Pharmacist and Medical Oncologist, V. Grigorova, R. Krasteva
- 14.50 – 15.10 Role Games to Overcome Burnout – D. Krastev, Ch. Harsev
- 15.10 – 15.30 Liver Carcinoma – Hepato vs Cholangio: Is it always as simple as that? A. Fakirova, B. Ilcheva
- 15.30 – 15.45 Exploration of Treatment of Prostate Ductal Adenocarcinoma in China, Y. Zhou
- 15.45 – 16.00 Advances in First-line Treatment of Metastatic Colorectal Cancer in China, J. Wang
- 16.00 – 16.20 How to Understand Results of Clinical Trials, I. Donev
- 16.20 – 16.40 The Additional Role of 18F-FDG PET/CT in the Initial Staging of Prostate Carcinoma: Insights from Clinical Cases, M. Mihaylova

Hall Pravets

16.40 – 17.40 Symposium Astellas

Moderator: R. Krasteva

Xtandi as a Choice of Treatment in Patients with mHSPC. Why? Ts. Tatarov, M. Kanarev, R. Manev

17.40 – 18.40 Symposium Novartis

Moderator: R. Krasteva

Clinical Experience with Ribociclib in Uni Hospital – Summary Analysis for the Period from March 2020 to March 2024, S. Nedeva
Ribociclib: Analysis of RWD in Bulgaria, M. Slavov

Clinical Experience with Taf/Mek, G. Shalamanova

Clinical Experience with Taf/Mek, A. Gerasimov

18.40 – 19.40 Symposium Eli Lilly

Moderator: A. Konsoulova

Aadjuvant Therapy for HR+, HER2-, Early Breast Cancer, Therapeutic Approach in Patients with Positive Lymph Nodes at High Risk of Relapse, R. Manev

HR+, HER2- Metastatic Breast Cancer and Patients with High Risk of Progression, Practical Approach, H. Hadjiev

CDK Therapy of Choice in Patients with HR+, HER2-, Metastatic Breast Cancer, with Visceral Disease at High Risk of Progression, I. Pandzharova

Hall Monovets

17.00 – 18.00 Symposium Pfizer

Navigating the Path: Optimizing the Management of CDK4/6 Inhibitors in Practice

Moderator: Y. Milusheva

Personalized Approach in Patient with HR+/HER2- mBC, Ts. Yordanov

Sharing Clinical Experience of Treatment of Patient with HR+/HER2- mBC, D. Velev

18.00 – 19.00 Symposium Swixx BioPharma

Shaping the Future: Harnessing the Power of Opdivo and Yervoy to Pave the Path to Prolonged Life

Moderator: S. Baka

Dual Immunotherapy with Limited Chemotherapy: Evidence and Experience, S. Baka

Clinical Cases Report with NSCLC Patients on Dual I-O, A. Tuparov

Clinical Experience Overview: Opdivo and Yervoy for NSCLC Patients, B. Iliev

19.00 – 19.20 Lecture Roche

What is New in the Treatment of Early HER2+ Breast Cancer, Ts. Tatarov

POSTER SESSION (all day)

19.20 – 19.30 Poster Awards

20.00 – 23.00 Dinner

